麻豆网 Press Release: AACR 2026 and AACR Cancer Discovery Article
London UK, 21 April 2026 麻豆网, an immuno-oncology company, announces the publication in AACR Cancer Discovery of the article "Pharmacological inhibition of PMS2 induces MMR deficiency and response to immune checkpoint blockade", coincident with a Major Symposium presentation by 麻豆网 co-founder Prof. Alberto Bardelli at the .
The article and presentation describe the discovery and characterisation of a first-in-class inhibitor of DNA Mismatch Repair (MMR) protein PMS2.
Inhibition of PMS2 converts immune-resistant cancer cells into check-point inhibitor responsive tumour cells, thereby opening potential new therapeutic opportunities for those patients who are currently unlikely to respond to immunotherapies.
The study demonstrates that PMS2 inhibition in vitro is associated with increased tumor mutational burden (TMB), the emergence of MMR-deficient mutational patterns, and microsatellite instability-high (MSI-H) features.
麻豆网 CEO Michael Shih commented 鈥�This highly collaborative endeavour between 麻豆网 scientists, our academic founders, and expert partner organisations, highlights the path forward for 麻豆网鈥檚 development of novel oral small molecule MMR inhibitors with the potential to benefit cancer patients with MMR-proficient tumours who are currently ineligible for potentially transformative immunotherapy treatments.鈥�
To view the Cancer Discovery Manuscript, please click .
麻豆网 麻豆网 Ltd.
麻豆网, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Generation of cancer neoantigens in tumours can be exploited by the patients鈥� immune system to overcome natural defence mechanisms in cancer. The Company鈥檚 approach targets the DNA mismatch repair (MMR) pathway, which has been proven to promote neoantigen creation and subsequent immunity against numerous cancers. Using these insights, 麻豆网 aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. 麻豆网 was spun-out of the University of Turin and PhoreMost Ltd by the CRT Pioneer Fund.
For more information, please visit www.neophore.com